Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Mark Hallett MD

Mark Hallett MD

Distinguished NIH Investigator Emeritus, National Institute of Neurological Disorders and Stroke, National Institutes of Health; Past-President, Functional Neurological Disorder Society, Bethesda, Maryland

Dr. Mark Hallett recently retired from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), but he remains connected there as Distinguished NIH Investigator Emeritus. He is also the current Past-President of the Functional Neurological Disorder Society. His research work mainly deals with principles of motor control and the pathophysiology of movement disorders.

Dr. Hallett is a Past President of the International Federation of Clinical Neurophysiology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the International Parkinson and Movement Disorder Society, and a past Vice-President of the American Academy of Neurology. He is a past Editor-in-Chief of Clinical Neurophysiology and a past Associate Editor of Brain. He has served, and is now serving, on many editorial boards. He is the recipient of many honors and has delivered many named lectures worldwide.

Disclosures

  • Advisory boards: BrainsWay; VoxNeuro; QuantalX
  • Consultant: Janssen

Recent Contributions to PracticeUpdate:

  1. 2024 Top Story in Neurology: Neuroprotection in Patients With Parkinson's Disease: Are We There Yet?
  2. BOLD Signal Variability as a Potential New Biomarker for Functional Neurological Disorders
  3. AAN 2024: Monoclonal Antibody That Binds Alpha-Synuclein Slows Progression of Parkinson Disease
  4. 2023 Top Story in Neurology: Artificial Intelligence and EEG
  5. A Spinal Cord Neuroprosthesis for Locomotor Deficits Due to Parkinson's Disease
  6. A Somatocognitive Action Network Alternates With Effector Regions in the Motor Cortex
  7. 2022 Top Story in Neurology: Diagnosing Functional Neurological Disorders
  8. 2021 Top Story in Neurology: Neurologic Disorders and Anti-IgLON5: Keep Autoimmunity in the Differential Diagnosis
  9. Cabozantinib for Plexiform Neurofibromas
  10. KMT2B-Related Disorders

Most Read This Week

Recently Updated